Pevonedistat hydrochloride is a small molecule commercialized by Takeda Pharmaceutical, with a leading Phase III program in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia). According to Globaldata, it is involved in 32 clinical trials, of which 15 were completed, 12 are ongoing, 1 is planned, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Pevonedistat hydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Pevonedistat hydrochloride is expected to reach an annual total of $2 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Pevonedistat hydrochloride Overview

Pevonedistat (MLN4924) is under development for the treatment of myelodysplastic syndrome, recurrent ovarian cancer, hematologic malignancies such as acute myelocytic leukemia, high risk myelodysplastic syndrome, relapsed/refractory multiple myeloma, myelofibrosis and chronic myelomonocytic leukemia,  acute lymphocytic leukemia, essential thrombocythemia, post-polycythemia vera myelofibrosis (PPV-MF). It is administered through intravenous route. It is a small molecule which acts by targeting NEDD8 Activating Enzyme (NAE) with potent anti-tumor activity. It was also under development for diffuse large B-cell lymphoma, Waldenstrom's macroglobulinemia, Hodgkin lymphoma, mantle cell lymphoma, metastatic melanoma and solid tumors including ovarian cancer, hepatocellular carcinoma, lung cancer, colon cancer, relapsed and refractory acute lymphocytic leukemia.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,096,551 million for the third quarter ended December 2022, an increase of 9.4% over the previous quarter.

For a complete picture of Pevonedistat hydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.